We are live on
!
Find out more
VanEck Associates Portfolio holdings
AUM
$133B
1-Year Est. Return
72.99%
This Fund
S&P 500
This Quarter
Est. Return
+9.33%
1 Year Est. Return
+72.99%
3 Year Est. Return
+157.94%
5 Year Est. Return
+206.35%
10 Year Est. Return
+770.56%
AUM
$19.6B
AUM Growth
+$1.29B
(+7.1%)
Cap. Flow
+$10.1M
Cap. Flow
% of AUM
0.05%
Top 10 Holdings %
Top 10 Hldgs %
29.33%
Holding
681
New
30
Increased
359
Reduced
247
Closed
34
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Franco-Nevada
FNV
|
+$346M |
| 2 |
Zoetis
ZTS
|
+$215M |
| 3 |
ATW
Atwood Oceanics
ATW
|
+$128M |
| 4 |
Marathon Petroleum
MPC
|
+$126M |
| 5 |
Alamos Gold
AGI
|
+$112M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
KUB
KUBOTA CORPORATION (ONE ADS REP 5 SHS COM)
KUB
|
+$255M |
| 2 |
ESV
Ensco Rowan plc
ESV
|
+$106M |
| 3 |
Archer Daniels Midland
ADM
|
+$97.7M |
| 4 |
SFD
SMITHFIELD FOODS,INC
SFD
|
+$79.6M |
| 5 |
DO
Diamond Offshore Drilling
DO
|
+$79M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Materials | 44.97% |
| 2 | Energy | 26.85% |
| 3 | Industrials | 4.46% |
| 4 | Healthcare | 4.41% |
| 5 | Consumer Staples | 3.56% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MDW
151
DELISTED
MIDWAY GOLD CORP (CANADA)
MDW
| $13.4M | 0.07% |
13,988,123
+925,930
| +7% | +$952K |
|
|
ARMH
152
DELISTED
ARM HOLDINGS PLC ADS
ARMH
| $13.2M | 0.07% |
273,974
-46,909
| -15% | -$1.98M |
|
153
Applied Materials
AMAT
$403B
| $12.8M | 0.07% |
732,589
-14,400
| -2% | -$230K |
|
154
Bristol-Myers Squibb
BMY
$133B
| $12.8M | 0.07% |
277,278
+18,833
| +7% | +$827K |
|
155
Merck
MRK
$322B
| $12.7M | 0.06% |
279,730
-63,671
| -19% | -$2.91M |
|
156
Micron Technology
MU
$930B
| $12.4M | 0.06% |
707,720
-114,686
| -14% | -$1.66M |
|
157
Sanofi
SNY
$103B
| $12.3M | 0.06% |
243,751
-6,252
| -3% | -$318K |
|
|
JOY
158
DELISTED
Joy Global Inc
JOY
| $11.9M | 0.06% |
233,896
-949
| -0.4% | -$48.4K |
|
159
AbbVie
ABBV
$443B
| $11.9M | 0.06% |
266,853
+13,587
| +5% | +$602K |
|
|
QGENF
160
DELISTED
QIAGEN NV
QGENF
| $11.9M | 0.06% |
555,659
+4,680
| +0.8% | +$100K |
|
161
GSK
GSK
$104B
| $11.7M | 0.06% |
187,020
-15,884
| -8% | -$1.02M |
|
162
AGNC Investment
AGNC
$12.4B
| $11.6M | 0.06% |
514,004
-57,791
| -10% | -$1.3M |
|
163
Bausch Health
BHC
$2.58B
| $11.2M | 0.06% |
107,676
-4,026
| -4% | -$392K |
|
164
AstraZeneca
AZN
$263B
| $11.1M | 0.06% |
213,731
+1,251
| +0.6% | +$62.8K |
|
165
Analog Devices
ADI
$179B
| $11M | 0.06% |
233,967
-9,559
| -4% | -$457K |
|
|
NVO
166
Novo Nordisk
NVO
$208B
| $11M | 0.06% |
648,220
+2,480
| +0.4% | +$41.7K |
|
|
SGEN
167
DELISTED
Seagen Inc. Common Stock
SGEN
| $10.9M | 0.06% |
248,464
+12,009
| +5% | +$500K |
|
|
BTU
168
DELISTED
PEABODY ENERGY CORP COM STK NEW (DE)
BTU
| $10.9M | 0.06% |
42,044
-389
| -0.9% | -$99.5K |
|
|
CRR
169
DELISTED
Carbo Ceramics Inc.
CRR
| $10.7M | 0.05% |
108,106
-26,080
| -19% | -$2.22M |
|
|
MDVN
170
DELISTED
MEDIVATION, INC.
MDVN
| $10.7M | 0.05% |
356,680
+14,364
| +4% | +$410K |
|
171
Teva Pharmaceuticals
TEVA
$40.8B
| $10.6M | 0.05% |
280,404
+3,224
| +1% | +$126K |
|
172
Abbott
ABT
$183B
| $10.3M | 0.05% |
310,664
+13,402
| +5% | +$470K |
|
173
Eli Lilly
LLY
$1.02T
| $10.3M | 0.05% |
204,461
-4,736
| -2% | -$248K |
|
174
Ionis Pharmaceuticals
IONS
$8.6B
| $10.3M | 0.05% |
+273,413
| New | +$8.17M |
|
|
BRD
175
DELISTED
BRIGUS GOLD CORP COM STK
BRD
| $10.3M | 0.05% |
17,089,922
+1,268,240
| +8% | +$700K |
|
Similar funds
VanEck Associates's Q3 2013 Portfolio in Review
As of Q3 2013, VanEck Associates held 681 positions worth $19.6B, up 7.1% from $18.4B the previous quarter. Its ten largest holdings account for 29% of the portfolio.
VanEck Associates's Q3 2013 filing shows 30 new, 359 increased, 247 reduced and 34 closed positions. Its largest new stake was Zoetis: 7,013,962 shares worth $218M. The largest sale was KUBOTA CORPORATION (ONE ADS REP 5 SHS COM), an estimated $255M.
By sector, the portfolio is most concentrated in Materials at 45% of assets, down from 45% a quarter earlier, followed by Energy and Industrials.
- VanEck Associates's largest Q3 2013 buy was Zoetis: 7,013,962 shares worth $218M.
- VanEck Associates added most to Franco-Nevada in Q3 2013, an estimated $346M increase.
- VanEck Associates's biggest Q3 2013 reduction was Ensco Rowan plc, cutting an estimated $106M.
- VanEck Associates fully exited KUBOTA CORPORATION (ONE ADS REP 5 SHS COM) in Q3 2013, selling an estimated $255M.
- VanEck Associates's ten largest holdings make up 29% of its $19.6B portfolio in Q3 2013.
- VanEck Associates opened 30 new positions and closed 34 in Q3 2013.
- VanEck Associates's portfolio value rose 7.1% quarter-over-quarter to $19.6B.
Based on VanEck Associates's 13F filing for Q3 2013, filed 14 Nov 2013.